Published in J Biomol Screen on February 20, 2006
Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol (2003) 1.86
Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos (2002) 1.45
Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol (2007) 1.25
CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos (2006) 1.24
Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common. Drug Metab Dispos (2007) 1.21
Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos (2004) 1.19
Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol (2005) 1.19
Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos (2010) 1.19
In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos (2003) 1.16
Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys (2003) 1.11
Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos (2002) 1.09
Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. Arch Biochem Biophys (2006) 1.08
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol (2005) 1.08
CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos (2009) 1.07
CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos (2007) 1.07
CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos (2010) 1.06
Your role and responsibilities in the manuscript peer review process. Am J Pharm Educ (2008) 1.05
Social network analysis to assess the impact of the CTSA on biomedical research grant collaboration. Clin Transl Sci (2014) 1.05
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics (2010) 1.03
Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br J Clin Pharmacol (2003) 1.02
KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther (2010) 1.02
Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos (2011) 1.01
Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry (2004) 1.00
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research. Pharmacotherapy (2008) 0.99
Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos (2009) 0.98
The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4. Arch Biochem Biophys (2010) 0.97
Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol (2007) 0.96
CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol (2005) 0.96
Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Dispos (2004) 0.95
Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol (2007) 0.93
Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos (2008) 0.93
CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos (2007) 0.93
Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity. Arch Biochem Biophys (2005) 0.92
Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab Dispos (2005) 0.92
Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol (2007) 0.92
Medication use in a rural gynecologic population: prescription, over-the-counter, and herbal medicines. Am J Obstet Gynecol (2004) 0.91
A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos (2003) 0.91
Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther (2006) 0.91
Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol (2008) 0.90
Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos (2002) 0.90
Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos (2011) 0.88
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab Dispos (2010) 0.88
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase. Bioorg Med Chem Lett (2008) 0.87
Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos (2006) 0.87
Formation of the active species of cytochrome p450 by using iodosylbenzene: a case for spin-selective reactivity. Chemistry (2007) 0.87
Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9. J Am Chem Soc (2006) 0.87
The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Dispos (2006) 0.87
Electrocatalytic drug metabolism by CYP2C9 bonded to a self-assembled monolayer-modified electrode. Drug Metab Dispos (2009) 0.86
Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Arch Biochem Biophys (2004) 0.85
Indirect genetic effects and the lek paradox: inter-genotypic competition may strengthen genotype x environment interactions and conserve genetic variance. Genetica (2008) 0.85
The role of PKR/eIF2α signaling pathway in prognosis of non-small cell lung cancer. PLoS One (2011) 0.85
Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos (2011) 0.85
Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles. Drug Metab Dispos (2006) 0.84
Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos (2011) 0.84
Absolute quantification of aldehyde oxidase protein in human liver using liquid chromatography-tandem mass spectrometry. Mol Pharm (2013) 0.84
An analysis of the regioselectivity of aromatic hydroxylation and N-oxygenation by cytochrome P450 enzymes. Drug Metab Dispos (2004) 0.84
In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract. Drug Metab Dispos (2009) 0.84
Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics (2012) 0.84
Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9. Biochemistry (2008) 0.84
Measurement of electron transfer through cytochrome P450 protein on nanopillars and the effect of bound substrates. J Am Chem Soc (2013) 0.84
Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab Dispos (2010) 0.83
Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol (2004) 0.83
Genetic and molecular analysis of a purple sheath somaclonal mutant in japonica rice. Plant Cell Rep (2011) 0.82
Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone. Arch Biochem Biophys (2008) 0.82
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9. J Med Chem (2007) 0.82
Three-dimensional quantitative structure-activity relationship analysis of cytochromes p450: effect of incorporating higher-affinity ligands and potential new applications. Drug Metab Dispos (2005) 0.82
Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme. Drug Metab Dispos (2012) 0.82
Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos (2008) 0.82
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction. Drug Metab Dispos (2011) 0.81
In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans. Drug Metab Dispos (2009) 0.80
Kinetic isotope effects implicate the iron-oxene as the sole oxidant in P450-catalyzed N-dealkylation. J Am Chem Soc (2004) 0.80
Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos (2008) 0.80
Application of cytochrome P450 drug interaction screening in drug discovery. Comb Chem High Throughput Screen (2010) 0.80
In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. Drug Metab Dispos (2012) 0.79
The use of immobilized cytochrome P4502C9 in PMMA-based plug flow bioreactors for the production of drug metabolites. Appl Biochem Biotechnol (2013) 0.79
Active site mutations of cytochrome p450cam alter the binding, coupling, and oxidation of the foreign substrates (R)- and (s)-2-ethylhexanol. Arch Biochem Biophys (2002) 0.79
Comparison of U.S. and Chinese pharmacy education programs. Am J Health Syst Pharm (2014) 0.78
Prediction of CYP-mediated drug interactions in vivo using in vitro data. IDrugs (2008) 0.78
Small molecule quantification by liquid chromatography-mass spectrometry for metabolites of drugs and drug candidates. Drug Metab Dispos (2011) 0.78
In vitro modulation of cytochrome P450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b(5) and methylene blue. Biochemistry (2010) 0.78
Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation. Toxicol Appl Pharmacol (2005) 0.78
Different enzyme kinetic models. Methods Mol Biol (2014) 0.77
[Enhancement of antigen presenting function of dendritic cells by IL-2 gene modification and its mechanism]. Zhonghua Xue Ye Xue Za Zhi (2002) 0.77
Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19. J Med Chem (2012) 0.77
Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab Dispos (2006) 0.77